Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$121.04 USD
+2.45 (2.07%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $121.00 -0.04 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.04 USD
+2.45 (2.07%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $121.00 -0.04 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
Revvity to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
MultiPlan Corporation (MPLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MultiPlan (MPLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
by Zacks Equity Research
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
QIAGEN's TB Testing Business Gets New Exposure at Global Summit
by Zacks Equity Research
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
by Zacks Equity Research
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
Reasons to Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
Company News for Jul 30, 2024
by Zacks Equity Research
Companies in The News Are: ON, AMG, RVTY, ARLP
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Revvity (RVTY) Tops Q2 Earnings Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 7.96% and 0.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Why Is Pediatrix Medical Group (MD) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cencora (COR) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Company News for Apr 30, 2024
by Zacks Equity Research
Companies In The News Are: DPZ, BEN, ON, RVTY.
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Revvity (RVTY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.